Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.

Participants will receive 1 gram of oleic sunflower oil for 12 weeks.

Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids

Fish Oil

Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
Fish oil that contains omega-3 fatty acids: Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids

Placebo

Total

Sex: Female, Male

Region of Enrollment

Markers of immune senescence will include change in the expression of the senescence markers CD28 and CD57 on the surface of peripheral CD4+ and CD8+ T lymphocytes. We will measure the percentage of CD4+ and CD8+ T lymphocytes that are CD28-/CD57- or CD28-/CD57+. We will subtract the percentage obtained at Week 12 from the baseline percentage to calculate the change scores.

Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation

Overall Study

Barbara Swanson

HIV Infection

Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids

Fish oil that contains omega-3 fatty acids

Gelcaps that contain 1 gram of oleic sunflower oil

Rush University Medical Center

Fish Oil for HIV-Related Inflamm-aging and Immune Senescence

Participants were randomized to one of two arms:
Intervention arm = fish oil Control arm = placebo.

All gelcaps were overencapsulated to mask their contents

The subjects take in 150g of Nutriall per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d. During the test period patients are treated with the first course of XELOX.

The subjects take in the same dose of Nutriall for the same duration as those in EN group. In addition, they take in 3 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.

The subjects take in the same dose of supportan for the same duration as those in EN group. In addition, they take in 6 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.

Gastric Cancer

Colorectal Cancer

Chemotherapy

The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.

Nutriall

The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.

LDEPA

The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.

The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.

HDEPA

Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)

First Affiliated Hospital, Sun Yat-sen University

Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor

Phase 3 Study of Enteral Nutrition Rich in Eicosapentaenoic Acid in Patients Receiving Chemotherapy for Gastric Cancer or Colorectal Cancer

Guanqing Sun

Sun Yat-sen University

Patients receive oral megestrol once daily and oral placebo twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.
Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.
Patients are followed every 6 months for 5 years.

Patients receive oral placebo once daily and an eicosapentaenoic acid (EPA)-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.
Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.
Patients are followed every 6 months for 5 years.

Patients receive oral megestrol once daily and an EPA-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.
Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.
Patients are followed every 6 months for 5 years.

Anorexia

Cachexia

eicosapentaenoic acid

megestrol acetate

placebo

CCOP - Scottsdale Oncology Program

Mayo Clinic

CCOP - Illinois Oncology Research Association

CCOP - Carle Cancer Center

CCOP - Cedar Rapids Oncology Project

CCOP - Iowa Oncology Research Association

Siouxland Hematology-Oncology

CCOP - Wichita

CCOP - Ochsner

CCOP - Ann Arbor Regional

CCOP - Duluth

Mayo Clinic Cancer Center

CentraCare Health Plaza

CCOP - Missouri Valley Cancer Consortium

Medcenter One Health System

CCOP - Merit Care Hospital

Altru Health Systems

CCOP - Toledo Community Hospital Oncology Program

CCOP - Geisinger Clinic and Medical Center

Allegheny General Hospital

Rapid City Regional Hospital

CCOP - Sioux Community Cancer Consortium

Tom Baker Cancer Center - Calgary

Cross Cancer Institute

British Columbia Cancer Agency - Centre for the Southern Interior

Nanaimo Cancer Clinic

British Columbia Cancer Agency

CancerCare Manitoba

Saint John Regional Hospital

Newfoundland Cancer Treatment and Research Foundation

William Osler Health Centre

Cancer Care Ontario-Hamilton Regional Cancer Centre

Kingston Regional Cancer Centre

Cancer Care Ontario-London Regional Cancer Centre

Trillium Health Centre

Ottawa Regional Cancer Centre

Peterborough Oncology Clinic

Toronto Sunnybrook Regional Cancer Centre

Toronto General Hospital

Queen Elizabeth Hospital, PEI

Maisonneuve-Rosemont Hospital

McGill University

L'Hopital Laval

Allan Blair Cancer Centre

Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite

Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Megestrol Acetate (Megace) Versus an N-3 Fatty Acid (EPA) Enriched Nutritional Supplement Versus Both for the Treatment of Cancer Cachexia and Anorexia

eicosapentaenoic acid/vemšana

Fish Oil for HIV-Related Inflamm-aging and Immune Senescence

Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor

Comparison of Megestrol and/or Omega-3 Fatty Acid-Enriched Nutritional Supplement in Treating Patients With Cancer-Related Weight Loss and Lack of Appetite

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne